G.k Edwards Md

U.S. News & World Report - Los Angeles Metro Best Regional Hospital in 16 Types of Care (2025-26), U.S. News & World Report - High Performing Hospital in Urology (2025-26), U.S. News & World Report - High Performing Hospital in Spinal Fusion (2025-26), Top 100 Oncology Hospitals in the U.S. 2024 - Becker's Hospital Review, American College of Radiology (ACR), Commission on Cancer (CoC) Accreditation - American College of Surgeons (ACS), National Accreditation Program for Breast Centers - American College of Surgeons (ACS), National Accreditation Program for Rectal Cancer Programs - American College of Surgeons (ACS), Accreditation Program for Excellence - American Society for Radiation Oncology (ASTRO)®, Foundation for the Accreditation of Cellular Therapy (FACT), Accountable Care Organizations (ACO) Accreditation - National Committee for Quality Assurance (NCQA), Pancreatic Center of Excellence - National Pancreas Foundation (NPF), Quality Oncology Practice Initiative (QOPI) Certification - American Society for Clinical Oncology (ASCO)

Providence Saint John’s is at the forefront of leading-edge treatment, renowned for our groundbreaking research and turning those discoveries into therapeutics that revolutionize patient care. Our researchers have published approximately 100 peer-reviewed studies across more than a dozen key specialties. Providence Saint John's has hundreds of patients enrolled in dozens of open clinical trials. Our world-class team of clinicians collaborate to provide patients with access to the latest evidence-based treatments and clinical trials. Providence cancer research provides options, and hope, for patients seeking advanced procedures and therapies. We’re proud of our long history of pioneering clinical trials, research and evidence-based therapies. We established the first cancer-care center west of the Mississippi. We also have over 90 years of radiation research. Among other groundbreaking firsts: We led the international trial of the first immunotherapy to be approved for patients with melanoma, as well as the first successful gene-engineered T-cell therapy for metastatic pancreatic cancer. As a Providence patient, you have the opportunity to participate in – or benefit from – the 1,300 new clinical trials that begin each year.